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Clinical PerspectiveWhat Is New?The use of the radial artery or the right internal thoracic artery is associated with a similar and statistically significant long‐term clinical benefit compared with the saphenous vein.There are no differences in operative risk or complications between the two arterial conduits, but deep sternal wound infection remains a concern with bilateral internal thoracic artery when skeletonization is not used.What Are the Clinical Implications?The results of our study support the superiority of the use of a second arterial over venous graft, and suggest the equivalence in long‐term and perioperative outcomes among RITA and radial artery.

Introduction {#jah33755-sec-0008}
============

One of the most important unresolved questions in contemporary coronary artery bypass (CABG) surgery is the choice of the conduit to complement the internal thoracic to left anterior descending artery anastomosis.

The radial artery (RA), the right internal thoracic artery (RITA), and the saphenous vein (SV) are all currently being used routinely, although the majority of the surgeons favor the SV.

Abundant observational evidence suggests a survival benefit for the use of arterial grafts, and the current guidelines encourage a wider use of the RA or the RITA, especially in patients with a long life expectancy.[1](#jah33755-bib-0001){ref-type="ref"}, [2](#jah33755-bib-0002){ref-type="ref"}, [3](#jah33755-bib-0003){ref-type="ref"}, [4](#jah33755-bib-0004){ref-type="ref"} However, the reported benefit of arterial grafts has not been confirmed in a large randomized controlled trial (RCT) , and it has been hypothesized that the survival benefit seen in observational studies may be due to unmatched confounders and treatment allocation bias.[5](#jah33755-bib-0005){ref-type="ref"}, [6](#jah33755-bib-0006){ref-type="ref"} An important additional unresolved question is the relative role of the RITA and RA. Although the RITA is biologically identical to the left internal thoracic artery, data comparing the patency rate and clinical outcome of the 2 arterial grafts has been contradictory and inconclusive.[7](#jah33755-bib-0007){ref-type="ref"}, [8](#jah33755-bib-0008){ref-type="ref"}

Network meta‐analysis (NMA) with adjusted indirect comparison among treatments is a useful technique to reduce the potential for heterogeneity or allocation biases, in particular when analyzing both RCTs and observational studies.[9](#jah33755-bib-0009){ref-type="ref"}

To date, the only published NMA comparing the SV, RITA and RA as the second conduit in CABG focused only on angiographic patency and not on clinical outcomes.[10](#jah33755-bib-0010){ref-type="ref"} Due to the well‐known discrepancy between occlusion of grafts to non--left anterior descending arteries and clinical outcomes,[11](#jah33755-bib-0011){ref-type="ref"} a similar analysis focusing on clinical end points is of particular relevance to the surgical community.

Here, we performed an NMA with the aim to specifically investigate the differences in late survival (primary outcome) and other clinical outcomes according to the type of second graft used for CABG.

Material and Methods {#jah33755-sec-0009}
====================

The authors declare that all supporting data are available within the article and its online supplementary files. This systematic review and NMA follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis statement.[12](#jah33755-bib-0012){ref-type="ref"}

Data Sources and Systematic Literature Review {#jah33755-sec-0010}
---------------------------------------------

Ovid\'s version of MEDLINE and EMBASE were searched from inception to February 2018 (full search strategy attached in Table [S1](#jah33755-sup-0001){ref-type="supplementary-material"}). Inclusion criteria were English language publications, adjusted or matched observational studies or RCTs comparing RA and/or SV and/or RITA as the second conduit for CABG. In addition, we searched recent meta‐analyses and reviews on this topic for potential additional studies. All citations were reviewed by 3 investigators independently (A.A., A.D.F., and M.R.), and any disagreements were resolved by consensus. In case of overlapping studies, the largest series were included.

Data Extraction and Quality Assessment {#jah33755-sec-0011}
--------------------------------------

Data extraction was performed independently by 2 investigators (A.A. and A.D.F.). The following variables were included: study demographics (sample size, number of centers, institutions involved, publication year, study period, design and country, length of follow‐up), patient demographics (age, sex, diabetes mellitus, and ejection fraction) and procedural (use of skeletonization) and postoperative data. The quality of the included studies was assessed by the Newcastle--Ottawa Scale (Table S2).[13](#jah33755-bib-0013){ref-type="ref"} Only RCTs and observational studies of high quality (Newcastle--Ottawa Scale score \>6) were included in the final analysis.

Outcomes {#jah33755-sec-0012}
--------

The primary outcome was all‐cause long‐term mortality. The secondary outcomes were operative mortality, perioperative stroke, perioperative myocardial infarction (MI), and deep sternal wound infection (DSWI), as defined in the original articles.

Two levels of analyses were conducted for all outcomes: (1) pairwise meta‐analysis between arterial grafts (with either RITA or RA) and SV and between RITA and RA, and (2) network meta‐analyses between RITA, RA, and SV.

Data Synthesis and Analysis {#jah33755-sec-0013}
---------------------------

### Pairwise meta‐analysis {#jah33755-sec-0014}

Late outcomes were pooled as the natural logarithm of the incident rate ratio (IRR) to account for potentially different follow‐up durations between the groups. We estimated the IRR through several means depending on the available study data. When hazard ratios for matched (preferentially)/adjusted cohorts were provided, we took the natural logarithm of the hazard ratio; the standard error was derived from the 95% CI or log rank *P* value.[14](#jah33755-bib-0014){ref-type="ref"} When Kaplan--Meier curves were present, we estimated the event rates from the curves using GetData Graph Digitizer software 2.26 (<http://getdata-graph-digitizer.com/>). In case of missing Kaplan--Meier curves, we used the reported event rates in order to calculate the IRR, as previously described.[15](#jah33755-bib-0015){ref-type="ref"}, [16](#jah33755-bib-0016){ref-type="ref"} Short‐term binary outcomes were pooled using log odds ratio (OR) with 95% CI using the generic inverse variance method.[9](#jah33755-bib-0009){ref-type="ref"} Random effect meta‐analysis was performed using meta and metafor packages in R (version 3.3.3 R Project for Statistical Computing).[17](#jah33755-bib-0017){ref-type="ref"}, [18](#jah33755-bib-0018){ref-type="ref"} Heterogeneity was reported as low (I^2^=0--25%), moderate (I^2^=26--50%), or high (I^2^ \>50%).[19](#jah33755-bib-0019){ref-type="ref"} In random‐effects meta‐analysis, the extent of variation among the effects observed in different studies (between‐study variance) is referred to as tau^2^ (ie, the variance of the true effect size parameters across the population of studies). Tau^2^ reflects the amount of true variance (heterogeneity), while tau is the estimated standard deviation of underlying true effects across studies, and they are used to describe the distribution of true effects; if there is no variance between studies, tau^2^ is low (or zero).[20](#jah33755-bib-0020){ref-type="ref"}, [21](#jah33755-bib-0021){ref-type="ref"}, [22](#jah33755-bib-0022){ref-type="ref"} We reported tau^2^ values throughout tables and figures, as appropriate.

Sensitivity analysis using leave‐one‐out analysis and publication bias assessment by funnel plot and Egger\'s test were conducted for the primary outcome. Subgroup analysis was used to compare the relative results of RITA and RA versus SV. Meta‐regression was used to explore the effect of age, sex, diabetes mellitus, and preoperative ejection fraction on the IRR for the primary outcome.

### Network meta‐analysis {#jah33755-sec-0015}

Network (multiple‐treatment) meta‐analysis was conducted in R (version 3.3.3 R Project for Statistical Computing) using the "netmeta" statistical package based on the method described by Rücker.[23](#jah33755-bib-0023){ref-type="ref"}, [24](#jah33755-bib-0024){ref-type="ref"}, [25](#jah33755-bib-0025){ref-type="ref"} Inconsistency was evaluated with Cochran\'s Q.[26](#jah33755-bib-0026){ref-type="ref"} Pooled log IRRs with 95% CIs was used to determine the relative effect estimates of late outcomes. ORs with 95% CIs were used for the binary outcomes. A random‐effects model was preferentially used to improve the model fit, but results using a fixed model were also reported.

Inconsistency in NMA was evaluated by conducting conventional pairwise meta‐analyses and testing consistency by comparing the direct and indirect evidence. The consistency equation used was μBC=μAC−μAB, where μAB is the treatment effect for treatment B compared with treatment A.[27](#jah33755-bib-0027){ref-type="ref"}, [28](#jah33755-bib-0028){ref-type="ref"} We used Cochran\'s Q statistic to assess inconsistency, and the presence of *P*\<0.05 signifies inconsistency. Statistical significance (at the 5% level) was declared when 95% CI did not cross the line of no effect. For the primary outcome, a network meta‐regression was used to relate the size of treatment effect to potential effect modifiers (mean age, percentage of female, percentage of patients with diabetes mellitus, and mean preoperative ejection fraction). Network meta‐regression was conducted using the logit transformation method with random‐effects model with no priori. The logit transformation was used as suggested by other authors.[29](#jah33755-bib-0029){ref-type="ref"}, [30](#jah33755-bib-0030){ref-type="ref"}

Results {#jah33755-sec-0016}
=======

Description of the Included Studies and of the Population {#jah33755-sec-0017}
---------------------------------------------------------

A total of 2455 studies were retrieved and 35 met inclusion criteria and were included in the final meta‐analysis (Figure [S1](#jah33755-sup-0001){ref-type="supplementary-material"}). Seven studies were international and multicenter; 11 studies were from the United States; 4 from Canada, 3 each from Italy and the United Kingdom; 2 each from Japan and Australia, and 1 each from Austria, Serbia, and Argentina (Tables [1](#jah33755-tbl-0001){ref-type="table"} and [2](#jah33755-tbl-0002){ref-type="table"}).[31](#jah33755-bib-0031){ref-type="ref"}, [32](#jah33755-bib-0032){ref-type="ref"}, [33](#jah33755-bib-0033){ref-type="ref"}, [34](#jah33755-bib-0034){ref-type="ref"}, [35](#jah33755-bib-0035){ref-type="ref"}, [36](#jah33755-bib-0036){ref-type="ref"}, [37](#jah33755-bib-0037){ref-type="ref"}, [38](#jah33755-bib-0038){ref-type="ref"}, [39](#jah33755-bib-0039){ref-type="ref"}, [40](#jah33755-bib-0040){ref-type="ref"}, [41](#jah33755-bib-0041){ref-type="ref"}, [42](#jah33755-bib-0042){ref-type="ref"}, [43](#jah33755-bib-0043){ref-type="ref"}, [44](#jah33755-bib-0044){ref-type="ref"}, [45](#jah33755-bib-0045){ref-type="ref"}, [46](#jah33755-bib-0046){ref-type="ref"}, [47](#jah33755-bib-0047){ref-type="ref"}, [48](#jah33755-bib-0048){ref-type="ref"}, [49](#jah33755-bib-0049){ref-type="ref"}, [50](#jah33755-bib-0050){ref-type="ref"}, [51](#jah33755-bib-0051){ref-type="ref"}, [52](#jah33755-bib-0052){ref-type="ref"}, [53](#jah33755-bib-0053){ref-type="ref"}, [54](#jah33755-bib-0054){ref-type="ref"}, [55](#jah33755-bib-0055){ref-type="ref"}, [56](#jah33755-bib-0056){ref-type="ref"}, [57](#jah33755-bib-0057){ref-type="ref"}, [58](#jah33755-bib-0058){ref-type="ref"}, [59](#jah33755-bib-0059){ref-type="ref"}, [60](#jah33755-bib-0060){ref-type="ref"}, [61](#jah33755-bib-0061){ref-type="ref"}, [62](#jah33755-bib-0062){ref-type="ref"}, [63](#jah33755-bib-0063){ref-type="ref"}, [64](#jah33755-bib-0064){ref-type="ref"}, [65](#jah33755-bib-0065){ref-type="ref"}

###### 

Characteristics of the Included Studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                                                    Study Period   Mean/Median SD Follow‐Up (Years)        Hospitals/Centers                                                                                  Type
  -------------------------------------------------------------- -------------- --------------------------------------- -------------------------------------------------------------------------------------------------- ----------
  Benedetto 2013[31](#jah33755-bib-0031){ref-type="ref"}         1996--2012     6.4±3.6                                 Papworth Hospital, Cambridge, England                                                              PSM

  Benedetto 2014[32](#jah33755-bib-0032){ref-type="ref"}         2001--2013     4.0±3.2                                 Harefield Hospital, London, United Kingdom                                                         PSM

  Benedetto 2017[33](#jah33755-bib-0033){ref-type="ref"}         1996--2015     10.2±4.5                                Bristol Heart Institute, United Kingdom                                                            PSM

  Buxton 1998[34](#jah33755-bib-0034){ref-type="ref"}            1985--1995     4.3                                     Austin and Repatriation Medical Center, University of Melbourne, Victoria, Australia               Adjusted

  Calafiore 2004[35](#jah33755-bib-0035){ref-type="ref"}         1986--1999     Overall: 7.3±4.8\                       University Hospital, Torino, Italy and "G D\'Annunzio" University, Chieti, Italy                   PSM
                                                                                RITA: 7.1±5.0\                                                                                                                             
                                                                                SV: 7.5±4.7                                                                                                                                

  Carrier 2009[36](#jah33755-bib-0036){ref-type="ref"}           1995--2007     10.0                                    Montreal Heart Institute, Montreal, Quebec, Canada                                                 Adjusted

  Cohen 2001[37](#jah33755-bib-0037){ref-type="ref"}             1994--1999     Max 3.0                                 Sunnybrook and Women\'s College Health Sciences Centre, Toronto, Canada                            PSM

  Dewar 1995[38](#jah33755-bib-0038){ref-type="ref"}             1984--1992     4.0                                     Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, Canada   PSM

  Goldman 2011[39](#jah33755-bib-0039){ref-type="ref"}           2003--2009     Max 1.0                                 Multicenter                                                                                        RCT

  Goldstone 2018[40](#jah33755-bib-0040){ref-type="ref"}         2006--2011     Median arterial: 5.3 (IQR: 3.8--6.7)\   Multicenter                                                                                        PSM
                                                                                Median venous: 5.2 (IQR: 3.7--6.6)                                                                                                         

  Grau 2015[41](#jah33755-bib-0041){ref-type="ref"}              1994--2013     Overall: 10.5±5.0\                      Columbia University College of Physicians and Surgeons, Ridgewood, NJ, United States               PSM
                                                                                RITA: 10.9±5.0\                                                                                                                            
                                                                                SV: 10.1±5.0                                                                                                                               

  Hayward 2013 (RAPCO)[42](#jah33755-bib-0042){ref-type="ref"}   1996--2004     6 (1.8--10.4)                           University of Melbourne, Victoria, Australia                                                       RCT

  Ioannidis 2001[43](#jah33755-bib-0043){ref-type="ref"}         1993--1996     NR                                      Multicenter                                                                                        Adjusted

  Janiec 2017[44](#jah33755-bib-0044){ref-type="ref"}            2001--2015     SV: 9.3 (4.2)\                          Multicenter                                                                                        Adjusted
                                                                                RA: 10.7 (4.1)\                                                                                                                            
                                                                                RITA: 5.5 (5.0)                                                                                                                            

  Kurlansky 2010[45](#jah33755-bib-0045){ref-type="ref"}         1972--1994     Overall: 11.0±0.5\                      Florida Heart Research Institute, Miami, FL, United States                                         Adjusted
                                                                                RITA: 12±.0.7.0\                                                                                                                           
                                                                                SV: 11.0±1.0                                                                                                                               

  LaPar 2015[46](#jah33755-bib-0046){ref-type="ref"}             2001--2013     30.0 days                               VCSQI database, Virginia, United States                                                            PSM

  Lin 2013[47](#jah33755-bib-0047){ref-type="ref"}               1997--2001     9.4 (5.7--11.9)                         Cedars‐Sinai Medical Center in Los Angeles, CA                                                     PSM

  Locker 2013[48](#jah33755-bib-0048){ref-type="ref"}            1993--2009     7.6                                     Mayo Clinic, Rochester, MN, United States                                                          Adjusted

  Lytle 2004[49](#jah33755-bib-0049){ref-type="ref"}             1971--1989     RITA: 16.2±2.4\                         The Cleveland Clinic Foundation, Cleveland, OH, United States                                      PSM
                                                                                SV: 16.3±2.5                                                                                                                               

  Nasso 2009[50](#jah33755-bib-0050){ref-type="ref"}             2003--2006     24.1±9.8 months                         Multicenter                                                                                        RCT

  Navia 2016[51](#jah33755-bib-0051){ref-type="ref"}             1996--2014     Median: 5.5 (IQR: 2.6--8.8)             Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina                                  PSM

  Parsa 2013[52](#jah33755-bib-0052){ref-type="ref"}             1984--2009     NR                                      Duke University Medical Center, Durham, NC, United States                                          Adjusted

  Petrovic 2015[53](#jah33755-bib-0053){ref-type="ref"}          2001--2003     Max 8.0                                 Belgrade University School of Medicine, Belgrade, Serbia                                           RCT

  Pusca 2008[54](#jah33755-bib-0054){ref-type="ref"}             1997--2006     NR                                      Emory University School of Medicine, Atlanta GA, United States                                     Adjusted

  Rosenblum 2016[55](#jah33755-bib-0055){ref-type="ref"}         2003--2013     Median: 2.8 (1.1--4.9)                  Emory University School of Medicine, Atlanta, GA, United States                                    PSM

  Ruttman 2011[56](#jah33755-bib-0056){ref-type="ref"}           2001--2010     Overall: 57.7 (3.0--112.0) months\      Innsbruck Medical University, Austria                                                              PSM
                                                                                RITA: 32.7 (3--111.0)\                                                                                                                     
                                                                                RA: 67.3 (3--112.0)                                                                                                                        

  Santarpino 2010[57](#jah33755-bib-0057){ref-type="ref"}        2003--2007     3.17±0.07                               Magna Graecia University of Catanzaro, Italy                                                       Adjusted

  Schwann 2016[58](#jah33755-bib-0058){ref-type="ref"}           1987--2011     4.7                                     Multicenter                                                                                        PSM

  Stevens 2004[59](#jah33755-bib-0059){ref-type="ref"}           1985--1995     Overall: 11.0±3.0\                      Montreal Heart Institute, Montreal, Quebec, Canada                                                 Adjusted
                                                                                RITA: 8.0±2.0\                                                                                                                             
                                                                                SV: 12.0±3.0                                                                                                                               

  Tarelli 2001[60](#jah33755-bib-0060){ref-type="ref"}           1988--1990     Overall: 9.2\                           Varese Hospital, Varese, Italy                                                                     PSM
                                                                                RITA: 9.2±2.8\                                                                                                                             
                                                                                SV: 9.1±2.5                                                                                                                                

  Tranbaugh 2010[61](#jah33755-bib-0061){ref-type="ref"}         1995--2009     7.7 (0.1--13.8)                         Beth Israel Medical Center, New York, NY, United States                                            PSM

  Tranbaugh 2017[62](#jah33755-bib-0062){ref-type="ref"}         1995--2012     RA: 8.8±4.0\                            Multicenter                                                                                        Adjusted
                                                                                RITA: 8.9±4.9\                                                                                                                             
                                                                                SV: 9.1                                                                                                                                    

  Tsuneyoshi 2015[63](#jah33755-bib-0063){ref-type="ref"}        2000--2013     6.1±7.8                                 "Kurashiki Central Hospital, Okayama, Japan"                                                       PSM

  Yoshida 2017[64](#jah33755-bib-0064){ref-type="ref"}           1997--2007     7.5±4.4                                 Fukui Cardiovascular Center, Shinbo, Fukui, Japan                                                  PSM

  Zacharias 2004[65](#jah33755-bib-0065){ref-type="ref"}         1996--2002     3.7±1.9                                 Mercy St Vincent Medical Center, Toledo, OH, United States                                         PSM
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IQR indicates interquartile range; NR, not reported; PSM, propensity score matched; RA, radial artery; RAPCO, Radial Artery Patency and Clinical Outcomes randomized trial; RCT, randomized controlled trial; RITA, right internal thoracic artery; SV, saphenous vein; VCSQI, Virginia Cardiac Services Quality Initiative.

###### 

Patient Demographics and Surgical Details

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                                                    Total Number   Age, y (Mean±SD)   Sex (Female) N (%)   Ejection Fraction (Mean±SD)   COPD N (%)    Diabetes Mellitus N (%)   RA Target Vessel Stenosis (%)   OPCAB/ONCAB Details                                                                                                                                                                          
  -------------------------------------------------------------- -------------- ------------------ -------------------- ----------------------------- ------------- ------------------------- ------------------------------- --------------------- ------------- ----------- ---------------- ---------------- ------------ --------------- ------------ ------------- ---------------- ------------- ------------------- -------------------------------
  RA vs SV studies                                                                                                                                                                                                                                                                                                                                                                                                         

  Benedetto 2013[31](#jah33755-bib-0031){ref-type="ref"}         809            809                ···                  64±10                         65±10         ···                       178 (22)                        157 (19.4)            ···           NR          NR               ···              83 (10.3)    92 (11.4)       ···          82 (10.1)     98 (12.1)        ···           NR                  OPCAB: RA, 27.8%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 25.5%

  Cohen 2001[37](#jah33755-bib-0037){ref-type="ref"}             478            956                ···                  60.7±8.8                      61.2±8.7      ···                       76 (15.9)                       152 (15.9)            ···           NR          NR               ···              40 (4.2)     23 (4.8)        ···          160 (33.5)    238 (24.9)       ···           NR                  NR

  Goldman 2011[39](#jah33755-bib-0039){ref-type="ref"}           366            367                ···                  61±8                          62±8          ···                       1 (1)                           5 (1)                 ···           NR          NR               ···              NR           NR              ···          154 (42)      153 (42)         ···           \>70                OPCAB: RA, 11%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 13%

  Lin 2013[47](#jah33755-bib-0047){ref-type="ref"}               260            260                ···                  70.6±8.7                      70.6±8.7      ···                       79 (30.4)                       77 (29.4)             ···           NR          NR               ···              39 (15.0)    33 (12.7)       ···          101 (38.8)    91 (33.5)        ···           NR                  OPCAB: RA, 16.5%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 18.1%

  Petrovic 2015[53](#jah33755-bib-0053){ref-type="ref"}          100            100                ···                  56.3±6.1                      57.1±6.5      ···                       27 (27)                         27 (27)               ···           48.8±10.7   48.0±10.8        ···              8 (8)        9 (9)           ···          39 (39)       43 (43)          ···           \>80                NR

  Santarpino 2010[57](#jah33755-bib-0057){ref-type="ref"}        150            180                ···                  72.19±9.9                     70.52±9.586   ···                       20 (11.1)                       49 (27.2)             ···           53.5±9.92   49.2±10.7        ···              27 (18)      24 (13.3)       ···          49 (27.2)     36 (24)          ···           \>80                OPCAB: RA, 28.9%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 24%

  Tranbaugh 2010[61](#jah33755-bib-0061){ref-type="ref"}         862            862                ···                  60.8±8.1                      60.8±9.2      ···                       203 (23.5)                      185 (22.5)            ···           48.3±11.8   47.7±13.2        ···              173 (20.1)   187 (21.7)      ···          314 (36.4)    332 (38.3)       ···           \>70                OPCAB: SV, 4.1%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RA, 1.3%

  Yoshida 2017[64](#jah33755-bib-0064){ref-type="ref"}           91             91                 ···                  64±8.8                        64.7±9.7      ···                       21 (23.1%)                      22 (24.2%)            ···           NR          NR               ···              NR           NR              ···          35 (38.5)     38 (41.8)        ···           87.2±13.2%          OPCAB: RA, 30.9%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV: 26.1%

  Zacharias 2004[65](#jah33755-bib-0065){ref-type="ref"}         925            925                ···                  63±10                         63±10         ···                       268 (28.1)                      271 (28.5)            ···           49±10       49±10            ···              174 (18.3)   177 (18.6)      ···          326 (34.2)    327 (34.3)       ···           From \<70 to \>90   NR

  RITA vs SV studies                                                                                                                                                                                                                                                                                                                                                                                                       

  Benedetto 2014[32](#jah33755-bib-0032){ref-type="ref"}         ···            750                750                  ···                           NR (Ranges)   NR (Ranges)               ···                             (21.2)                (10.8)        ···         \<50% in 22.1%   \<50% in 13.2%   ···          10.6            7.7          ···           31.5             15.9          ···                 OPCAB: RITA, 71.7%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 72.5%

  Buxton 1998[34](#jah33755-bib-0034){ref-type="ref"}            ···            1557               1269                 ···                           64.9±9        58.6±9                    ···                             \(22\)                (10.6)        ···         \<50% in 24.2%   \<50% in 4.9%    ···          NR              NR           ···           19.9             6.8           ···                 NR

  Calafiore 2004[35](#jah33755-bib-0035){ref-type="ref"}         ···            570                570                  ···                           60.8±9.0      60.7±8.3                  ···                             (17.5)                (19.3)        ···         59.3±13.8        59.4±13.1        ···          3               2.8          ···           24.2             24.2          ···                 OPCAB: RITA, 32.5%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 24.2%

  Carrier 2009[36](#jah33755-bib-0036){ref-type="ref"}           ···            5420               1235                 ···                           68±8          61±9                      ···                             29                    16            ···         NR               NR               ···          NR              NR           ···           31               21            ···                 NR

  Dewar 1995[38](#jah33755-bib-0038){ref-type="ref"}             ···            765                377                  ···                           NR            NR                        ···                             16.6                  15.4          ···         NR               NR               ···          NR              NR           ···           19.3             17.7          ···                 NR

  Grau 2015[41](#jah33755-bib-0041){ref-type="ref"}              ···            1006               1006                 ···                           62±9          60±9                      ···                             12.1                  10.4          ···         50±12            51±11            ···          5.9             5.1          ···           13.3             11            ···                 OPCAB: RITA, 49.2%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV 49.2%

  Ioannidis 2001[43](#jah33755-bib-0043){ref-type="ref"}         ···            830                867                  ···                           65.2 (9.8)    62.0±10.3                 ···                             37.3                  22.6          ···         42.0 (13.1)      46.5±13.7        ···          19.3            13           ···           38.4             25.6          ···                 All ONCAB

  Kurlansky 2010[45](#jah33755-bib-0045){ref-type="ref"}         ···            2369               2215                 ···                           67.5±9.4      62.9±10.0                 ···                             25.7                  14.9          ···         CAT              CAT              ···          NR              NR           ···           27.3             20.8          ···                 All ONCAB

  LaPar 2015[46](#jah33755-bib-0046){ref-type="ref"}             ···            1333               1333                 ···                           59±10         56±10                     ···                             18.7                  14.3          ···         55 (50--60)      55 (50--60)      ···          11.4            10.7         ···           34.9             18.2          ···                 NR

  Lytle 2004[49](#jah33755-bib-0049){ref-type="ref"}             ···            1152               1152                 ···                           57.8±8.3      57.5±8.1                  ···                             14                    12            ···         NR               NR               ···          NR              NR           ···           12               12            ···                 NR

  Navia 2016[51](#jah33755-bib-0051){ref-type="ref"}             ···            485                485                  ···                           NR            63.7±9.1                  ···                             NR                    9.8           ···         NR               NR               ···          NR              4.2          ···           NR               25.9          ···                 ONCAB: RITA, 0.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 61%

  Parsa 2013[52](#jah33755-bib-0052){ref-type="ref"}             ···            16 881             728                  ···                           64 (median)   59 (median)               ···                             28.5                  19.8          ···         52% (median)     51% (median)     ···          8.2             3.9          ···           29.9             14.7          ···                 NR

  Pusca 2008[54](#jah33755-bib-0054){ref-type="ref"}             ···            10 212             599                  ···                           62.9 (10.7)   58.0±0.34                 ···                             2810 (27.5)           17.4          ···         50.1 (12.7)      51.6±11.4        ···          1564 (15.3) 7   12           ···           3725 (36.5)      25.2          ···                 OPCAB: SV, 39%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RITA, 90%

  Rosenblum 2016[55](#jah33755-bib-0055){ref-type="ref"}         ···            306                306                  ···                           63.8±10.6     59.0±10.1                 ···                             28.7                  15.5          ···         51.7±12.4        52.2±11.0        ···          6.3             1.8          ···           43.8             27.6          ···                 ONCAB: SV, 33.7%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RITA: 18.8%

  Stevens 2004[59](#jah33755-bib-0059){ref-type="ref"}           ···            2547               1835                 ···                           63±9          57±9                      ···                             25                    12            ···         NR               NR               ···          6               4            ···           18               12            ···                 NR

  Tarelli 2001[60](#jah33755-bib-0060){ref-type="ref"}           ···            150                150                  ···                           59.3±8.3      56.5±8.2                  ···                             17.3                  7.3           ···         54.5±13.5        57.2±13.6        ···          NR              NR           ···           24.7             11.3          ···                 NR (presumably all ONCAB)

  RA vs RITA studies                                                                                                                                                                                                                                                                                                                                                                                                       

  Benedetto 2017[33](#jah33755-bib-0033){ref-type="ref"}         764            ···                764                  58±8                          ···           57±9                      53 (6.9)                                              54 (7.1)      CAT         ···              CAT              36 4.7       ···             38 5.0       49 (6.5)      ···              39 (5.1)      \>75                OPCAB: RA, 69%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RITA, 44.9%

  Hayward 2013 (RAPCO)[42](#jah33755-bib-0042){ref-type="ref"}   198            ···                196                  59.2 (37.9--71.0)             ···           59.5 (36.2--70.9)         23 (12)                         ···                   18 (9)        NR          ···              NR               NR           ···             NR           22 (11%)      ···              20 (10%)      \>70                All ONCAB

  Ruttman 2011[56](#jah33755-bib-0056){ref-type="ref"}           277            ···                277                  57.8±9.0                      ···           56.6±9.6                  28 (10.1)                       ···                   28 (10.1)     52.9±12.1   ···              54.9±10.8        92 (33.2)    ···             92 (33.2)    62 (22.4)     ···              59 (21.3)     NR                  NR

  Tsuneyoshi 2015[63](#jah33755-bib-0063){ref-type="ref"}        118            ···                118                  67.9±10                       ···           68.3±8                    30 (25)                         ···                   22 (19)       CAT         ···              CAT              2 (1.6)      ···             2 (1.6)      53 (45)       ···              63 (53)       "Severe"            All OPCAB

  RA vs SV vs RITA studies                                                                                                                                                                                                                                                                                                                                                                                                 

  Goldstone 2018[40](#jah33755-bib-0040){ref-type="ref"}         4268           5813               1574                 62.1±10.5                     62.5±10.4     61.7±10.3                 614 (14.5)                      916 (15.8)            229 (14.3)    55.5±12.0   55.6±12.0        56.1±12.0        629 (14.8)   856 (14.7)      250 (15.6)   1525 (35.7)   2066 (35.5)      528 (33.7)    NR                  NR

  Janiec 2017[44](#jah33755-bib-0044){ref-type="ref"}            1036           46 343             862                  64.5 (9.7)                    66.4 (8.4)    63.9 (9.0)                277 (26.7%)                     8879 (19.2%)          146 (16.9%)   CAT         CAT              CAT              39 (5.7%)    2551 (6.9%)     59 (7.7%)    212 (20.7%)   11 077 (24.3%)   206 (24.0%)   NR                  OPCAB: SV, 2.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RA, 2.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RITA 6.7%

  Locker 2013[48](#jah33755-bib-0048){ref-type="ref"}            169            1153 (Matched)     589                  NR                            59±10         NR                        NR                              187 (16.2)            NR            NR          58±13            NR               NR           86 (7.5)        NR           NR            221 (19.2)       NR            NR                  OPCAB: SV, 4.4% MultArt, 3.3%

  Nasso 2009[50](#jah33755-bib-0050){ref-type="ref"}             202            202                201                  70.5±3.1                      69.7±3.5      69.2±3.9                  87 (43.1)                       84 (41.6)             88 (43.8)     CAT                          CAT              57 (28.2)    56 (27.7)       55 (27.4)    73 (36.1)     77 (38.1)        76 (37.8)     \>70                All ONCAB

  Schwann 2016[58](#jah33755-bib-0058){ref-type="ref"}           551            551                551                  58.4±10.2                     60.6±10.3     59.5±9.7                  72 (13)                         97 (18)               77 (14)       52±10       54±10            53±11            46 (8.3)     39 (7.1)        41 (7.4)     100 (18)      94 (17)          93 (17)       \>75                ONCAB: RITA, 98%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RA, 96%\
                                                                                                                                                                                                                                                                                                                                                                                                                           SV, 95%

  Tranbaugh 2010[61](#jah33755-bib-0061){ref-type="ref"}         4577           7073               1674                 60.3±9.7                      67.4±9.9      64.9±10.3                 1033 (22.6)                     2448 (34.6)           460 (27.5)    49.1±10.9   47.2±12.9        46.4±14.3        781 (17.1)   1804 (25.5)     149 (8.9)    702 (37.2)    2704 (38.2)      597 (35.7)    LCX:\>70\           OPCAB: SV, 3.5%\
                                                                                                                                                                                                                                                                                                                                                                                                       RCA:\>90            RA, 3.0%\
                                                                                                                                                                                                                                                                                                                                                                                                                           RITA, 1.4%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAT indicates reported as categories; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EF, ejection fraction; LCX, left circumflex artery territory; MultiArt, multiple arterial grafting group; NR, not reported; ONCAB, on‐pump coronary artery bypass; OPCAB, off‐pump coronary artery bypass; RA, radial artery; RCA, right coronary artery territory; RITA, right internal thoracic artery; SV, saphenous vein.

A total of 149 902 patients were included (RA, 16 201; SV, 112 018; and RITA, 21 683) from 4 RCTs (n=1932) and 31 observational studies (n=147 970). Demographics of the included studies are shown in Tables [1](#jah33755-tbl-0001){ref-type="table"} and [2](#jah33755-tbl-0002){ref-type="table"}.

The number of patients in the individual studies ranged from 182 to 48 241 (91--4577 in the RA group, 91--46 343 in the SV group, and 118--2215 in the RITA group). The mean age ranged from 56.0 to 72.1 (56.3--72.1 years in the RA group, 57.1--70.6 years in the SV group, and 56.2--69.2 in the RITA group). Female sex ranged from 1.1 to 43.8% (1.0--43.1% in the RA group, 1.1--41.6% in the SV group, and 7.3--43.8% in the SV group). Most patients had a normal or low‐normal ejection fraction (range 42--59.4%). The incidence of diabetes mellitus ranged from 5.1 to 53.2% (6.5--45.1% in the RA group, 12.0--43.8% in the SV group, and 5.1--53.3% in the RITA group).

Pairwise Meta‐Analysis {#jah33755-sec-0018}
----------------------

The main results of the pairwise meta‐analysis are summarized in Table [3](#jah33755-tbl-0003){ref-type="table"}.

###### 

Outcomes Summary of the Pairwise Meta‐Analysis

  Model                     Studies[\*](#jah33755-note-0006){ref-type="fn"}   Point Estimate[†](#jah33755-note-0007){ref-type="fn"}   95% CI         Overall Effect (Z‐Value, *P* Value)   Heterogeneity (I^2^, *P* Value)   Tau^2^   Interpretation
  ------------------------- ------------------------------------------------- ------------------------------------------------------- -------------- ------------------------------------- --------------------------------- -------- --------------------
  Long term mortality                                                                                                                                                                                                                 
  RA/SV                     11                                                0.81                                                    0.73 to 0.90   ···                                   47, 0.04                          0.0110   Better in RA
  RITA/SV                   17                                                0.80                                                    0.73 to 0.86   ···                                   73, \<0.01                        0.0136   Better in RITA
  RITA/RA                   9                                                 0.96                                                    0.83 to 1.11   ···                                   57, 0.02                          0.0204   ND
  ART/SV                    28                                                0.80                                                    0.75 to 0.85   −6.93, \<0.0001                       66, \<0.01                        0.0115   Better in ART
  Perioperative DSWI                                                                                                                                                                                                                  
  RA/SV                     8                                                 1.10                                                    0.80 to 1.51   ···                                   0, 0.48                           0        ND
  RITA/SV                   14                                                1.33                                                    1.04 to 1.69   ···                                   24, 0.20                          0.0463   Higher in RITA
  RITA/RA                   6                                                 2.22                                                    1.09 to 4.54   ···                                   40, 0.14                          0.2795   Higher in RITA
  ART/SV                    21                                                1.27                                                    1.05 to 1.54   2.41, 0.0159                          14, 0.27                          0.0264   Higher in ART
  Perioperative mortality                                                                                                                                                                                                             
  RA/SV                     7                                                 0.66                                                    0.46 to 0.95   −2.27, 0.0234                         29, 0.21                          0.0599   Better in RA
  RITA/SV                   17                                                0.68                                                    0.53 to 0.87   −3.11, 0.0019                         56,                               0.1327   Better in RITA
  RITA/RA                   7                                                 1.76                                                    1.21 to 2.55   2.98, 0.0029                          11.7, 0.34                        0.0310   Better in RA
  ART/SV                    24                                                0.68                                                    0.55 to 0.83   −3.79, 0.0002                         49.1, 0.004                       0.1043   Better in ART
  Perioperative stroke                                                                                                                                                                                                                
  RA/SV                     7                                                 0.73                                                    0.54 to 1.00   ···                                   0, 0.72                           0        Better in RA
  RITA/SV                   11                                                0.85                                                    0.62 to 1.16   ···                                   36, 0.11                          0.0875   ND
  RITA/RA                   5                                                 0.87                                                    0.45 to 1.68   ···                                   29, 0.23                          0.1653   ND
  ART/SV                    18                                                0.80                                                    0.65 to 0.98   −2.11, 0.0350                         14, 0.29                          0.0266   Better in arterial
  Perioperative MI                                                                                                                                                                                                                    
  RA/SV                     7                                                 0.67                                                    0.42 to 1.07   ···                                   0, 0.56                           0        ND
  RITA/SV                   8                                                 0.79                                                    0.65 to 0.96   ···                                   0, 0.65                           0        Better in RITA
  RITA/RA                   2                                                 0.32                                                    0.03 to 3.13   ···                                   61.1, 0.11                        1.67     ND
  ART/SV                    15                                                0.77                                                    0.64 to 0.92   −2.82, 0.0048                         0, 0.73                           0        Better in ART

ART indicates all arterial grafts; DSWI, deep sternal wound infections; MI, myocardial infarction; ND, no difference; RA, radial artery; RITA, right internal thoracic artery; SV, saphenous vein.

Articles reporting the outcomes in RA, RITA, and SV cohorts were included as 3 studies (RA/SV, RITA/SV, and RITA/RA).

Incidence rate ratio was used for long‐term mortality, while odds ratio was used for operative mortality and perioperative outcomes.

At a mean follow‐up of 6.9 years, the use of any arterial graft (RA or RITA) was associated with lower long‐term mortality compared with the use of the SV (IRR, 0.80; 95% CI, 0.75--0.85). There was a significantly higher risk of DSWI (OR 1.27; 95% CI, 1.05--1.54) in the arterial graft group. Operative mortality (OR, 0.68; 95% CI, 0.55--0.83), perioperative MI (OR, 0.77; 95% CI, 0.64--0.92) and perioperative stroke (OR, 0.80; 95% CI, 0.65--0.98) were lower in the arterial graft group.

The use of the RA was associated with lower long‐term mortality (IRR, 0.81; 95% CI, 0.73--0.90) at a mean follow‐up of 8.1 years compared with the SV. Operative mortality (OR, 0.66; 95% CI, 0.46--0.95) and perioperative stroke (OR, 0.73; 95% CI, 0.54--1.00) were lower in the RA group, while the risk of perioperative MI (OR, 0.67, 95% CI, 0.42--1.07), and DSWI were similar (OR, 1.10; 95% CI, 0.80--1.51).

The use of the RITA was associated with lower long‐term mortality (IRR, 0.80; 95% CI, 0.73--0.86) at mean 8.5 years follow‐up compared with SV. Perioperative MI (OR, 0.79; 95% CI, 0.65--0.96) and operative mortality (OR, 0.68; 95% CI, 0.53--0.87) were lower in the RITA arm. There was no difference in perioperative stroke (OR, 0.85; 95% CI, 0.62--1.16), while the risk of DSWI higher in the RITA group (OR, 1.33; 95% CI, 1.04--1.69).

When directly comparing the 2 arterial grafts, the use of RITA was associated with similar long‐term mortality (IRR, 0.96; 95% CI, 0.83--1.11) at 7.1 years' mean follow‐up compared with the RA. The risk of perioperative MI (OR, 0.32; 95% CI, 0.03--3.13) and perioperative stroke (OR, 0.87; 95% CI, 0.45--1.68) were similar between the 2 arterial grafts. There was a significantly higher risk of DSWI (OR, 2.22; 95% CI, 1.09--4.54) and operative mortality (OR, 1.76, 95% CI, 1.21--2.55) in the RITA group. When limiting the analysis to the studies where the skeletonization technique was used for ITA harvesting, no difference in DSWI between the RA and RITA groups was found (Figure [S2](#jah33755-sup-0001){ref-type="supplementary-material"}).

A subgroup analysis for the primary outcome comparing the results of RCT versus non‐RCT studies is provided in Figure [S3](#jah33755-sup-0001){ref-type="supplementary-material"}.

Leave‐one‐out analysis was robust for the primary outcome in the main analysis (arterial grafts versus SV (Figure [S4A](#jah33755-sup-0001){ref-type="supplementary-material"}). Funnel plot Egger\'s test intercept for the primary outcome in arterial versus venous comparison was −0.64±0.46, *P*=0.17 (Figure [S4B](#jah33755-sup-0001){ref-type="supplementary-material"}).

Network Meta‐Analysis {#jah33755-sec-0019}
---------------------

The results of the NMA are summarized in [Figure](#jah33755-fig-0001){ref-type="fig"} and Tables [S3 and S4](#jah33755-sup-0001){ref-type="supplementary-material"}.

![Full network meta‐analytic estimates (expressed as incidence rate ratio \[IRR\] and odds ratio \[OR\] with 95% credible interval) for the different outcomes using random and fixed models respectively. **A**, Long‐term mortality (SV is associated with higher long‐term mortality compared with RA;IRR=1.23, 95%CI=1.12--1.34; τ^2^=0.0127; I^2^=64%); **B**, Operative mortality (SV is associated with higher operative mortality compared with RA expressed as OR,1.71; 95%CI.1.17--2.52; τ^2^=0.1219; I^2^=48.7%); **C**, Perioperative MI (SV is associated with similar perioperative MI compared with RA expressed as OR=1.32, 95%CI=0.84--2.07; τ^2^=0.0041; I^2^=2.1%); **D**, Perioperative stroke (SV is associated with similar perioperative stroke compared with RA expressed as OR=1.30, 95%CI=0.90--1.88; τ^2^=0.0573; I^2^=22%); **E**, Perioperative DSWI (SV is associated with similar perioperative DSWI compared with RA expressed as OR=0.98, 95%CI=0.67--1.46; τ^2^=0.0671; I^2^=25.4%I). DSWI indicates deep sternal wound infections; MI, myocardial infarction; RA, radial artery; RITA, right internal thoracic artery; SV, saphenous vein.](JAH3-8-e010839-g001){#jah33755-fig-0001}

The use of the SV was associated with higher late mortality (IRR, 1.23; 95% CI, 1.12--1.34) and operative mortality (OR, 1.71; 95% CI, 1.17--2.52) compared with the RA. The risk of perioperative MI (OR, 1.32; 95% CI, 0.84--2.07), perioperative stroke (OR, 1.30; 95% CI, 0.90--1.88), and DSWI (OR, 0.98; 95% CI, 0.67--1.46) was not statistically different when compared with the RA.

The use of the SV was associated with higher late mortality (IRR, 1.26; 95% CI, 1.17--1.35), operative mortality (OR, 1.45; 95% CI, 1.14--1.84), and perioperative MI (OR, 1.30; 95% CI, 1.06--1.61) compared with the RITA. The risk of perioperative stroke (OR, 1.24; 95% CI, 0.93--1.64) was not statistically different, and the risk of DSWI (OR, 0.71; 95% CI, 0.55--0.91) was lower with the SV compared with the RITA.

The use of the RITA was associated with similar late mortality (IRR, 0.98; 95% CI, 0.89--1.07) and perioperative MI (OR, 1.01; 95% CI, 0.62--1.65) compared with the RA. There was a trend toward higher risk of DSWI in the RITA group (OR, 1.39; 95% CI, 0.92--2.1), while operative mortality and stroke were similar for the 2 arteries.

At network meta‐regression, mean age, percentage of female, percentage of patients with diabetes mellitus, and mean preoperative ejection fraction were not found to significantly modify the treatment effect (Figure [S5](#jah33755-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah33755-sec-0020}
==========

The balance between possible better long‐term clinical and angiographic outcomes of arterial grafts and the potential risk of harvesting site complications and the increased technical complexity associated with their use has been the center of a continuous debate over the past 25 years.[66](#jah33755-bib-0066){ref-type="ref"} Also, the relative efficacy of the RITA and RA as the second arterial grafts remains controversial.[7](#jah33755-bib-0007){ref-type="ref"}

Several pairwise meta‐analyses on the topic have been published previously.[1](#jah33755-bib-0001){ref-type="ref"}, [67](#jah33755-bib-0067){ref-type="ref"}, [68](#jah33755-bib-0068){ref-type="ref"} However, pairwise meta‐analyses have known limitations in terms of heterogeneity of the included studies and potential for treatment allocation bias. NMAs have been proposed to overcome the limitations of the pairwise comparison, especially when summarizing the evidence of RCTs and observational studies.[9](#jah33755-bib-0009){ref-type="ref"}, [69](#jah33755-bib-0069){ref-type="ref"} It has been suggested that NMA can be superior to classical pairwise analyses, especially in case of comparison of a new treatment to a standard one.[70](#jah33755-bib-0070){ref-type="ref"}

This is the first NMA specifically addressing the differences in clinical outcomes according to the type of second graft used for CABG. The only published network meta‐analysis on the subject focused only on the patency rates of conduits and did not include clinical outcomes.[10](#jah33755-bib-0010){ref-type="ref"} Due to the demonstrated absence of a consistent correlation between angiographic failure and clinical events,[11](#jah33755-bib-0011){ref-type="ref"} a deeper understanding of the clinical impact of the type of second conduit used for CABG seems of major relevance.

The results of our study support the superiority of the use of a second arterial over venous graft, and suggest the equivalence in long‐term and perioperative outcomes between the RITA and RA.

The superior midterm patency rate of arterial grafts (especially the RA) has been convincingly demonstrated in RCTs and observational studies.[50](#jah33755-bib-0050){ref-type="ref"}, [71](#jah33755-bib-0071){ref-type="ref"}, [72](#jah33755-bib-0072){ref-type="ref"}, [73](#jah33755-bib-0073){ref-type="ref"}, [74](#jah33755-bib-0074){ref-type="ref"} A large amount of observational evidence also suggests a clinical benefit in terms of survival and event‐free survival for the use of the RA or the RITA instead of the SV as the second graft.[1](#jah33755-bib-0001){ref-type="ref"}, [7](#jah33755-bib-0007){ref-type="ref"}, [75](#jah33755-bib-0075){ref-type="ref"}, [76](#jah33755-bib-0076){ref-type="ref"} However, we have recently shown how unmatched confounders are present even in the best comparative observational studies and suggested that a treatment allocation bias may be responsible for the better clinical outcome of patients receiving more than 1 arterial graft.[6](#jah33755-bib-0006){ref-type="ref"}

This type of bias is potentially present even in the present meta‐analysis, but the additional power and precision of NMA in defining relations and interactions between treatments from the aggregated estimates of all the available evidence should permit a more efficient comparison among different strategies.[9](#jah33755-bib-0009){ref-type="ref"}

Our results are in line with those of a recent patient‐level meta‐analysis on the comparison between the RA and the SV.[76](#jah33755-bib-0076){ref-type="ref"} However, at first sight, our results appear to contradict the overall neutral findings of the ART (Arterial Revascularization Trial), where on the primary intention‐to‐treat analysis, there was no difference in survival between single and bilateral ITA grafts at 10 years (in press). However, 40% of patients in the ART received a different treatment from that initially proposed and an as‐treated analysis showed a significant survival benefit in patients receiving \>1 arterial graft, consistent with the results of the current study. Difference in sample size and length of follow‐up and the fact that in observational studies the revascularization strategy is based on surgical judgment and not mandated by protocol are possible explanations for these apparent contradictions.

A key finding of this study is the demonstration of equivalence between the RITA and RA with respect to all the short‐ and long‐term clinical outcomes. Of note, in our analysis, the relative survival benefit of the RITA and RA compared with the SV were identical (SV versus RITA and RA, IRR, 1.26; 95% CI, 1.17--1.35). Although there was a trend toward higher risk of DSWI with RITA, this risk became nonsignificant in a subgroup analysis of studies where the skeletonization of ITA was employed. This finding is in accordance with what was reported by previous meta‐analyses[7](#jah33755-bib-0007){ref-type="ref"} and by a post hoc analysis of the ART.[77](#jah33755-bib-0077){ref-type="ref"}

The literature on the comparison between the RITA and RA is discordant. We previously published a pairwise meta‐analysis of the propensity‐matched studies comparing the 2 arterial grafts and found that the use of the RITA was associated with a 25% relative reduction in the risk of long‐term mortality.[7](#jah33755-bib-0007){ref-type="ref"} The reason underlying the discrepancy between our previous meta‐analysis and the present findings is probably related to the different sample size (149 902 patients with 6.9 years of follow‐up for the present analysis versus 15 374 patients and a range of 45--168 months of follow‐up for the previous pairwise comparison). Also, our previous analysis did not include 2 recent large studies comparing the 2 arterial grafts.[33](#jah33755-bib-0033){ref-type="ref"}, [78](#jah33755-bib-0078){ref-type="ref"} Finally, the use of NMA and direct/indirect comparisons allow for better precision around estimates compared with pairwise comparisons.

Of note, in a large study the Society of Thoracic Surgeons National Database of \>1.4 million patients, Schwann et al[8](#jah33755-bib-0008){ref-type="ref"} showed significantly higher perioperative mortality and risk of DSWI using the RITA, but not the RA, versus the SV as the second graft---findings that were also demonstrated in the present study. The authors also described a significant volume‐to‐outcome relation for the use of the RITA but not of the RA. Similarly, in a meta‐analysis of 34 bilateral internal thoracic artery (BITA) series and 27 000 BITA patients, we recently identified a highly significant BITA use‐to‐outcome relationship for long‐term survival and incidence of DSWI that was independent from the well‐known CABG volume/outcome effect.[78](#jah33755-bib-0078){ref-type="ref"} These findings suggest that BITA grafting may be more technically demanding than the use of the single internal thoracic artery and that a volume/outcome relation can explain the marginally increased operative risk in the RITA arm.

A key point when using the RA for CABG is the degree of target vessel stenosis. It has been shown that the patency rate of RA grafts is strongly influenced by the degree of target coronary stenosis.[79](#jah33755-bib-0079){ref-type="ref"}, [80](#jah33755-bib-0080){ref-type="ref"}, [81](#jah33755-bib-0081){ref-type="ref"} In fact, a target vessel stenosis \>70% was a common criterion for using the RA in the studies included in this meta‐analysis (Table [2](#jah33755-tbl-0002){ref-type="table"}).

This study shares the usual limitations of meta‐analyses of observational studies.[82](#jah33755-bib-0082){ref-type="ref"} Despite statistical adjustment and the use of NMA, between‐studies heterogeneity remains a source of bias. Important details such as the etiology of follow‐up of death, the protocols used to reduce the risk of DSWI (with the exception of skeletonization of the ITA), and the incidence of repeat revascularization were not systematically retrievable and could not be included in our analyses.

Additionally, we recognize that despite including only adjusted studies, the presence of unmeasured confounders and treatment allocation biases cannot be excluded.[6](#jah33755-bib-0006){ref-type="ref"} However, the NMA approach utilized and the low‐moderate‐grade heterogeneity found across the studies should have attenuated these biases.

In conclusion, in an NMA of adjusted observational and randomized studies comparing the RA, the RITA, and the SV as the second conduit for CABG, we found that the use of the RITA or the RA was associated with a similar long‐term clinical benefit compared with the use of the SV. No differences in late and operative mortality and postoperative complications was found between the 2 arterial conduits, although DSWI remains a concern after BITA grafting if skeletonization is not used.
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**Table S1.** Search Strategy

**Table S2.** Newcastle‐Ottawa Scale for the Included Studies

**Table S3.** Comparison of Direct and Indirect Estimates to Assess Inconsistency Within Network Loops for the Outcomes

**Table S4.** Rank Scores With Probability Rank of Different Graft Groups With the Greatest Reduction in Outcomes Within the Different Treatment Groups (RITA, RA, and SV) Where the Closer to One Equates to the Probability the Therapy Leads to the Greatest Reduction

**Figure S1.** Preferred Reporting Items for Systematic Reviews and Meta‐Analysis flow chart of study selection.

**Figure S2. A**, Forest plot showing subgroup differences for skeletonization on deep sternal wound infection (DSWI) in RITA vs RA/SVG pairwise comparisons (subgroup difference *P*=0.1933); **B**, Forest plot showing subgroup differences for skeletonization on deep sternal wound infection (DSWI) in RITA vs SVG pairwise comparisons (subgroup difference *P*=0.4194); **C**, Forest plot showing subgroup differences for skeletonization on deep sternal wound infection (DSWI) in RITA vs RA pairwise comparisons (subgroup difference *P*=0.2786). RA indicates radial artery; RITA, right internal artery; SV, saphenous vein.

**Figure S3.** Long‐term mortality for arterial grafts (RA/RITA) vs SV in RCT vs non‐RCT trials (subgroup difference *P*=0.4897). ART indicates all arterial grafts; RA, radial artery; RITA, right internal thoracic artery; SV, saphenous vein.

**Figure S4.** Leave one out (**A**) and funnel plot (**B**) for the primary analysis. RA indicates radial artery; RITA, right internal artery; SV, saphenous vein.

**Figure S5.** Network meta‐regression for long term mortality. **A**, Mean age; **B**, Female percent; **C**, Diabetes mellitus percent; **D**, Ejection fraction (EF) percent.
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